mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trial
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 119
- 试验地点
- 1
- 主要终点
- Pathologic complete response (pCR)
研究概览
简要总结
Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI will receive 6 cycles of neoadjuvant treatment with mFOLFOX6 (Arm A) vs. mFOLFOX6 + aflibercept (Arm B) followed by surgery.
详细描述
Patients with locally advanced rectal cancer are generally recommended to receive preoperative radiotherapy or radiochemotherapy. The advantage of combined-modality therapy in rectal cancer is that it has reduced local pelvic recurrence - a dreaded and morbid event - to rates of about 10%. There is good quality evidence that preoperative radiotherapy reduces local recurrence but there is little if any impact on overall survival. One strategy to reduce the distant recurrence rate, and thereby increase the cure rate, would be to introduce systemic treatment earlier to prevent dissemination of micrometastases. The present trial is designed to compare two neoadjuvant chemotherapy regimens in patients with non-metastatic T3 CRM-negative rectal cancers using quality-controlled MRI of the pelvis as a main inclusion criterion. This strategy is believed to reduce acute and long-term toxicity caused by preoperative radiotherapy and to administer effective systemic chemotherapy early in the course of disease as neoadjuvant chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years on day of signing informed consent
- •Signed and dated informed consent, and willing and able to comply with protocol requirements
- •WHO/ECOG Performance Status (PS) 0-1
- •Diagnosis of rectal adenocarcinoma
- •Candidate for sphincter-sparing surgical resection prior to neoadjuvant therapy according to the primary surgeon, i.e. no patient will be included for whom surgeon indicates need for abdomino-perineal resection (APR) at baseline.
- •Clinical staging is based on the combination of the following assessments:
- •Physical examination by the primary surgeon
- •CT scan of the chest/abdomen
- •Pelvic MRI
- •Rigid rectoscopy / endoscopic ultrasound (ERUS).
- •Both examinations (i.e. MRI and ERUS) are mandatory.
- •The tumor has to fulfill the following criteria:
- •No symptomatic bowel obstruction
- •Locally advanced rectal and rectosigmoid cancer, i.e. lower border of tumor > 5 cm and < 16 cm from anal verge as determined by rigid rectoscopy
- •MRI criteria:
- •Lower border of tumor below a line defined by promontorium and symphysis, regardless of the criterion "< 16 cm from anal verge as determined by rigid rectoscopy".
- •No evidence that tumor is adjacent to (defined as within 2 mm of) the mesorectal fascia on MRI (i.e. CRM > 2 mm)
- •Only T3-tumors are included, i.e infiltration into perirectal fat < 10 mm provided CRM > 2 mm
- •Note: MRI criteria are used for the definition of T3 tumor (i.e. exclusion of T2 and T4 situation).
- •Hematological status:
- •Neutrophils (ANC) ≥ 2 x 10^9/L
- •Platelets ≥ 100 x 10^9/L
- •Hemoglobin ≥ 9 g/dL (previous transfusion of packed blood cells allowed)
- •Adequate renal function:
- •Serum creatinine level ≤ 1.5 x upper limit normal (ULN) or ≤ 1.5 mg/dl
- •Creatinine clearance ≥ 30 ml/min
- •Adequate liver function:
- •Serum bilirubin ≤ 1.5 x upper limit normal (ULN)
- •Alkaline phosphatase < 3 x ULN
- •AST and ALT < 3 x ULN
- •Proteinuria < 2+ (dipstick urinalysis) or ≤ 1 g/24hour or ≤ 500mg/dl
- •Regular follow-up feasible
- •For female patients of childbearing potential, negative pregnancy test within 1 week (7 Days) prior of starting study treatment
- •Female patients of childbearing potential (i.e. did not undergo surgical sterilization - hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and is not post-menopausal for at least 24 consecutive months) must commit to using high effective and appropriate methods of contraception until at least 6 months after the end of study treatment such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally
- •Fertile male patients with a partner of childbearing potential must commit to using high effective and appropriate methods of contraception (details see above) until at least 9 months after the end of study treatment.
排除标准
- •Distant metastases (CT scans of thorax and abdomen are mandatory)
- •cT2 and cT4 tumors (defined by MRI criteria)
- •Exclusion of potentially compromised CRM as defined by MRI criteria (i.e. > 2 mm distance from CRM)
- •Prior antineoplastic therapy for rectal cancer
- •History or evidence upon physical examination of CNS metastasis
- •Uncontrolled hypercalcemia
- •Pre-existing permanent neuropathy (NCI-CTCAE grade ≥ 2)
- •Uncontrolled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy
- •Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy, radiotherapy)
- •Treatment with any other investigational medicinal product within 28 days prior to study entry
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency
- •Treatment with CYP3A4 inducers unless discontinued > 7 Days prior to randomization
- •Any of the following in 3 months prior to inclusion:
- •Grade 3-4 gastrointestinal bleeding
- •Treatment resistant peptic ulcer disease
- •Erosive esophagitis or gastritis
- •Infectious or inflammatory bowel disease
- •Diverticulitis
- •Any active infection within 2 weeks prior to study inclusion
- •Vaccination with a live, attenuated vaccine within 4 weeks prior to the first administration of the study medication
- •Other concomitant or previous malignancy, except:
- •Adequately treated in-situ carcinoma of the uterine cervix
- •Basal or squamous cell carcinoma of the skin
- •Cancer in complete remission for > 5 years
- •Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days prior to study entry
- •Pregnant or breastfeeding women
- •Patients with known allergy to any constituent to study drugs
- •History of myocardial infarction and/or stroke within 6 months prior to randomization, NYHA class III and IV congestive heart failure
- •Severe renal insufficiency (creatinin clearance < 30 ml/min)
- •Bowel obstruction
- •Contra-indication to the assessment by MRI
- •Involvement in the planning and/or conduct of the study (applies to both Sanofi staff and/or staff of Sponsor and study site)
- •Patient who might be dependent on the sponsor, site or the investigator
- •Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG
- •Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
研究组 & 干预措施
Arm A
6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
干预措施: Oxaliplatin (Drug)
Arm A
6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
干预措施: 5-FU (Drug)
Arm A
6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
干预措施: Leucovorin (Drug)
Arm B
6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
干预措施: Oxaliplatin (Drug)
Arm B
6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
干预措施: 5-FU (Drug)
Arm B
6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
干预措施: Leucovorin (Drug)
Arm B
6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
干预措施: Aflibercept (Biological)
结局指标
主要结局
Pathologic complete response (pCR)
时间窗: 20 weeks
number of patients with a pCR finding divided by the number of patients in the analysis set pCR will be assessed in a standardized manner independently by a central pathology
次要结局
- Dose intensities of study medication(12 weeks)
- Type, incidence and severity of AEs, SAEs(20 weeks)
- Dose reduction or discontinuation of study drug due to adverse events(20 weeks)
- Rate of treatment discontinuation due to toxicity(20 weeks)
- Type, incidence and severity of laboratory abnormalities(20 weeks)
- Rate of patients with R0-wide resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)(20 weeks)
- Rate of patients with R0-narrow resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)(20 weeks)
- Rate of patients with R1 resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)(20 weeks)
- Rate of number of patients with R0-wide, R0-narrow (according to CRM definitions in S3 guideline-Version 1.1 August 2014), R1 and locoregional R2 resection(20 weeks)
- Disease-free survival (DFS)(44 weeks)
- Relapse-free survival (RFS) in resected patients(44 weeks)
- Mortality after surgery(20 weeks)
- Physical examination(20 weeks)
- Rate of patients with locoregional R2 resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)(20 weeks)
- Overall survival (OS) rate(44 weeks)
- Downstaging ability in resected patients using a standardized regression grading (Dworak regression grading)(20 weeks)
- Vital signs(20 weeks)
- Downsizing ability in resected patients using a standardized regression grading (Dworak regression grading)(20 weeks)
- Type, incidence and severity of perioperative medical events within 28 days after surgery are assessed. Perioperative morbidity is categorized according to the Clavien-Dindo-Classification(20 weeks)
- ECOG(20 weeks)